Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen, Roche Sign Pharmacogenomics Deal

Premium

NEW HAVEN, Conn.--CuraGen said it signed a target discovery and pharmacogenomics collaboration with the Swiss life-sciences company Hoffmann-La Roche last week. Roche said it will apply CuraGen's bioinformatics and genomics expertise to the discovery of animal nutrition and human health products. The deal is designed to evaluate existing product candidates, discover new targets, and facilitate the development of drugs and diagnostic tests.

Roche will integrate data from CuraGen's SeqCalling and GeneCalling databases into it existing discovery efforts. Terms of the two-year renewable agreement were not disclosed, but Peter Fuller, CuraGen's vice-president of business development, said the successful assessment of late-stage product development candidates would increase the likelihood of CuraGen receiving near-term revenues.

Filed under

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.